表达免疫原的重组金丝雀痘病毒的研发

Development of Recombinant Canarypox Viruses Expressing Immunogens.

作者信息

Garanzini Débora, Del Médico-Zajac María Paula, Calamante Gabriela

机构信息

Instituto de Biotecnología, CICVyA-INTA, N. Repetto y de los Reseros, Hurlingham, Buenos Aires, Argentina.

Instituto Nacional de Producción de Biológicos, ANLIS "Dr. Carlos G. Malbrán", Av. Vélez Sarsfield, 563, Ciudad Autónoma de Buenos Aires, Argentina.

出版信息

Methods Mol Biol. 2017;1581:15-28. doi: 10.1007/978-1-4939-6869-5_2.

DOI:10.1007/978-1-4939-6869-5_2

PMID:28374241

Abstract

Canarypox viruses (CNPV) are excellent candidates to develop recombinant vector vaccines due to both their capability to induce protective immune responses and their incompetence to replicate in mammalian cells (safety profile). In addition, CNPV and the derived recombinants can be manipulated under biosafety level 1 conditions. There is no commercially available system to obtain recombinant CNPV; however, the methodology and tools required to develop recombinant vaccinia virus (VV), prototype of the Poxviridae family, can be easily adapted. This chapter provides protocols for the generation, plaque isolation, molecular characterization, amplification and purification of recombinant CNPV.

摘要

金丝雀痘病毒（CNPV）是开发重组载体疫苗的理想候选者，这是因为它们既能诱导保护性免疫反应，又无法在哺乳动物细胞中复制（安全性良好）。此外，CNPV及其衍生的重组体可以在生物安全1级条件下进行操作。目前尚无用于获得重组CNPV的商业化系统；然而，开发痘病毒科原型重组痘苗病毒（VV）所需的方法和工具可以很容易地进行调整。本章提供了重组CNPV的产生、蚀斑分离、分子特征分析、扩增和纯化的方案。